Mutant-Allele Tumor Heterogeneity, a Favorable Biomarker to Assess Intra-Tumor Heterogeneity, in Advanced Lung Adenocarcinoma.

Front Oncol · 2022 · PMC9286753 · PMID 35847947

Europe PMC DOI

hedged sentence

0.0520

closest p · 1.0× alpha

0.0520

boldest claim

The sentences

showed a trendP = 0.052so close (0.05 < p ≤ 0.1)

Patients with stage IV disease showed a trend to have a higher MATH score than those with stage III ( P = 0.052).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.